New Cancer Gene Therapy Findings from Nagoya University Reported (Sting Activator 2'3'-cgamp Enhanced Hsv-1-based Oncolytic Viral Therapy).

Předmět:	CANCER genes GENE therapy CANCER treatment GENETIC vectors HERPESVIRUS diseases ONCOLOGY
Zdroj:	Cancer Gene Therapy Week; 2024, p45-45, 1p
Abstrakt:	A recent study conducted by researchers at Nagoya University in Japan explores the potential of combining oncolytic viruses (OVs) with stimulator of interferon genes (STING) agonists for cancer gene therapy. OVs selectively replicate in tumor cells and modify the tumor microenvironment, while STING agonists activate dendritic cells and induce antitumor immunity. The study found that the combination therapy of an HSV-1-based OV called C-REV with a membrane-impermeable STING agonist called 2'3'-GAMP enhanced antitumor immune responses and systemic antitumor immunity. These findings suggest a promising strategy for improving cancer treatment. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu